» Articles » PMID: 19798470

Anti-CV2 Associated Cerebellar Degeneration After Complete Response to Chemoradiation of Head and Neck Carcinoma

Overview
Journal J Neurooncol
Publisher Springer
Date 2009 Oct 3
PMID 19798470
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Paraneoplastic cerebellar degeneration is a rare neurological disorder that frequently precedes the detection of malignancy. Here, we report the case of a 60 year-old woman with locally advanced squamous cell carcinoma of the tongue who developed a subacute cerebellar syndrome associated with the presence of anti-CV2/CRMP5 antibodies in the cerebrospinal fluid, after achieving complete remission of the primary tumor and the involved cervical lymph nodes by chemoradiation. The patient's symptoms on presentation were dizziness and gait unsteadiness. On examination she showed dysarthria, nystagmus and limb and gait ataxia. The diagnosis of paraneoplastic cerebellar syndrome was made on the basis of the clinical findings and immunological testing that revealed the presence of anti-CV2/CRMP5 antibodies in the patient's cerebrospinal fluid. This syndrome, which is very rare in association with head and neck cancer, commonly precedes the detection of malignancy by a year or more and has been documented in only a few cases after completion of anticancer treatment.

Citing Articles

An overview on CV2/CRMP5 antibody-associated paraneoplastic neurological syndromes.

Wang S, Hou H, Tang Y, Zhang S, Wang G, Guo Z Neural Regen Res. 2023; 18(11):2357-2364.

PMID: 37282453 PMC: 10360094. DOI: 10.4103/1673-5374.371400.


Paraneoplastic Cerebellar Degeneration with Anti-CV2/CRMP5 Antibodies in Ovarian Cancer: Case Report and Review of the Literature.

Juarez-Vignon Whaley J, Carrera-Muinos A, Hernandez-Gutierrez K, Rodriguez-Cid J, Otero-Cerdeira M, Garcia-Montes V Case Rep Oncol. 2022; 14(3):1799-1805.

PMID: 35111012 PMC: 8787574. DOI: 10.1159/000519969.


Anti-CV2/CRMP5 antibody-positive paraneoplastic neurological syndromes with chronic intestinal pseudo-obstruction in a small-cell lung cancer patient: a case report and literature review.

Yan J, Chen Z, Liang Y, Yang H, Cao L, Zhou Y J Int Med Res. 2020; 48(12):300060520974466.

PMID: 33305627 PMC: 7734506. DOI: 10.1177/0300060520974466.


Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer.

Huemer F, Melchardt T, Trankenschuh W, Neureiter D, Moser G, Magnes T BMC Cancer. 2015; 15:996.

PMID: 26694863 PMC: 4687318. DOI: 10.1186/s12885-015-2020-4.


Paraneoplastic cerebellar degeneration with anti-CV2/CRMP5 antibodies and prostate adenocarcinoma.

Aliprandi A, Terruzzi A, Rigamonti A, Bazzigaluppi E, Tremolizzo L, Ferrarese C Neurol Sci. 2015; 36(8):1501-3.

PMID: 25686614 DOI: 10.1007/s10072-015-2113-5.

References
1.
Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche J, Carpentier A, Rogemond V . Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2008; 80(4):412-6. PMC: 2664637. DOI: 10.1136/jnnp.2007.138016. View

2.
Frey A, Di Canzio J, Zurakowski D . A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods. 1999; 221(1-2):35-41. DOI: 10.1016/s0022-1759(98)00170-7. View

3.
Bonakis A, Papageorgiou S, Mandellos D, Galani E, Kalfakis N . Acute onset paraneoplastic cerebellar degeneration. J Neurooncol. 2007; 84(3):329-30. DOI: 10.1007/s11060-007-9368-5. View

4.
GREENBERG H . Paraneoplastic cerebellar degeneration. A clinical and CT study. J Neurooncol. 1984; 2(4):377-82. DOI: 10.1007/BF00178121. View

5.
Buxtorf K, Hubscher E, Panizzon R . Bazex syndrome. Dermatology. 2001; 202(4):350-2. DOI: 10.1159/000051680. View